Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v69-v82
Authors: D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. M. Ribera and C. Buske
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations. This figure qualifies ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. The new ESMO Clinical Practice Guidelines provide up-to-date information on the management of acute lymphoblastic leukaemia, and include recommendations for diagnosis and pathology/molecular biology, staging and risk assessment as well as detailed treatment strategies for early and advanced disease.